Pharmacologic Management of Outpatient Bronchiectasis with Acute Exacerbation, Wheezing, and Chronic Infection

Acute Exacerbation Management

Administer oral empiric antibiotics for 14 days in patients with bronchiectasis experiencing an acute exacerbation (cough, fever, leukocytosis). [1][2]
Obtain sputum for routine bacterial culture and mycobacterial culture before starting antibiotics whenever feasible. [3][4]
If the patient has a prior isolation of Pseudomonas aeruginosa, select an anti‑pseudomonal regimen. [1][2]

Prescribe a long‑acting β₂‑agonist (LABA) or long‑acting muscarinic antagonist (LAMA) to relieve airway obstruction associated with wheezing in bronchiectasis. 5
Short‑acting bronchodilators may be used for acute symptom relief, although supporting evidence is limited. 5

Perform sputum culture during clinical stability to identify chronic colonisation with P. aeruginosa or other pathogens. [1][3]
Collect at least three sputum samples for mycobacterial culture to exclude non‑tuberculous mycobacteria (NTM) before initiating long‑term macrolide therapy. [2][6]
When the first isolate is P. aeruginosa, consider a 2‑week systemic eradication course. 7

First‑line options: inhaled antibiotics (colistin or gentamicin) or long‑term macrolide (azithromycin 250 mg three times weekly or erythromycin).** [7][1]2
Select the regimen based on patient preference and individualized risk assessment. 7
Conduct a bronchoprovocation or challenge test before initiating inhaled antibiotics to confirm tolerability. [1][6]

Refer patients for airway‑clearance physiotherapy to optimise sputum expectoration. [1][2]3
Ensure up‑to‑date pneumococcal and influenza vaccinations. 7
Screen for and manage comorbidities such as gastro‑oesophageal reflux disease, sinus disease, and immunodeficiency. [3][4]

Before starting long‑term macrolides, verify at least one negative NTM culture to minimise the risk of macrolide‑resistant NTM. [1][2]6
Use macrolides cautiously in patients with significant hearing loss or balance disorders. [1][2]
Avoid inhaled aminoglycosides if creatinine clearance is < 30 mL/min, and do not co‑prescribe nephrotoxic agents. [1][2]6
Apply similar caution with inhaled aminoglycosides in patients with pre‑existing auditory or vestibular impairment. [1][2]
Re‑evaluate patients every 6 months to assess efficacy, toxicity, and the continued need for long‑term antibiotics. [5][6]
Perform periodic sputum cultures and susceptibility testing; in‑vitro resistance may not always translate to clinical failure. [1][6]
If ≥ 5 exacerbations occur annually despite optimal therapy, consider cyclic intravenous antibiotics every 2–3 months. [1][2]3

Initiation of prophylactic antibiotics should be restricted to respiratory specialists. [1][5]6
Long‑term antibiotic regimens are reserved for patients with recurrent exacerbations (≥ 3 per year) after maximising non‑pharmacologic measures. [7][1]3
A lower treatment threshold may be appropriate for patients who remain symptomatic between exacerbations or who are at high risk for severe episodes (e.g., immunosuppressed). [1][6]